Company Resources

Comparison of therapeutic recommendations based on OneChoice plus® with recommendations from infectious disease specialists for the treatment of bacteremia and urinary tract infections in patients hospitalized at HNERM, during the period of October to December 2025. Study in the Reba by Carlos Chávez. Ethics Committee NO Protocol

Accuracy of therapeutic recommendations from a clinical decision support system: Onechoice® report based on phenotypic outcomes, in relation to clinical infectious disease physicians and other specialties in the treatment of urinary tract infections (UTIs) diagnosed in Lima, Peru. Ethics Committee. NO, but I'm almost sure we submitted the protocol. Accepted and presented at the Pan-American Congress of Infectious Diseases 2025

Clinical utility of FilmArray BCID and resistance gene detection in bacteraemia: Five-year retrospective analysis from Lima, Peru.Ethics Committee. YES (FACSA-CEI/145-08-2024) con el título PI 145-24: “Eficiencia diagnóstica de un programa de optimización del diagnóstico de bacteriemias con FilmArray Blood Culture Identification Panel (BCID) en un laboratorio clínico de Lima, Perú" Abstract  approved by ASM Washington, June 2026 and Abstract submitted to ESCMID

Antimicrobial Stewardship in the Era of AI: A Head-to-Head Comparison of the Arkstone Machine Learning HTL Algorithm and Large Language Models in Real-World Infectious Disease Cases. Falta la evaluación de los expertos #1, 2 y 3.Ethics committee:: YES  (FACSA-CEI/ 168-10-2025) con el título: PI 168-25: “Gestión de antimicrobianos en la era de la IA: Comparación directa del algoritmo HITL de aprendizaje automático Arkstone y modelos de lenguaje de gran tamaño en casos reales de enfermedades infecciosas”

Clinical Utility and Cost-Effectiveness of Molecular Diagnostic-Guided Antimicrobial Therapy in Sepsis: A Retrospective Cohort Study". Carolina Study. Ethics committee: YES  (FACSA-CEI/ 004-02-2025) with the title: PI 004-25: “Evaluación retrospectiva del rol de la microbiología molecular en la optimización del tratamiento antibiótico y los resultados clínicos". (Abstract submitted to ESCMID as: Effect of rapid molecular microbiology on clinical and economic outcomes in sepsis and bacteremia in resource-limited settings. And approved by ASM Washington, June 2026.

Comparison of OneChoice® AI-based clinical decision support recommendations with infectious disease specialists and non-specialists for bacteremia treatment in Lima, Peru. En Plos One Peer Review. Ethics committee: YES  (FACSA-CEI/093-06-2025) with the title: “Precisión de la recomendación terapéutica de un sistema de apoyo a la toma de decisiones clínicas: Informe OneChoice® basado en resultados moleculares y fenotípicos con especialistas en enfermedades infecciosas y no infecciosas en el tratamiento de bacteriemias en Lima, Perú".

From Molecular Diagnostics to Artificial Intelligence: Impact of an Integrated Bloodstream Infection Program on Diagnostic Concordance and Time-to-Therapy(Abstract submitted to ESCMID as: Accelerating bacteraemia management with molecular-AI versus molecular-phenotypic AIantimicrobial recommendations: A prospective study in a resource-limited setting). And approved by ASM Washington, June 2026. Ethics committee: YES (FACSA-CEI_173-11-25) but with the title: PI 173-25: “Impacto de un Programa Integrado de Diagnóstico Molecular e Inteligencia Artificial en Infecciones del Torrente Sanguíneo: Evaluación de Concordancia Diagnóstica y Tiempo hasta Terapia Apropiada.”